FOLH1 and prostate cancer: Preliminary results of 37 patients with recurrent prostate cancer and rising PSA levels (background ratio between 18.8 and 28.3) indicated that the labeling of PSMA ligand with 68Ga could detect relapses and metastases of prostate carcinoma with high contrast compared to normal tissue [23].